This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (March 2023) |
Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients (APIs) and intermediates, headquartered in Hyderabad.[5][6][2][7] The company manufactures and custom synthesizes generic APIs, intermediates.[8][9] The company also manufactures and supplies nutraceutical ingredients through its subsidiary, Divi's Nutraceuticals.[10] Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization.[11]
![]() Divi's Laboratories' logo | |
Formerly | Divi's Research Centre |
---|---|
Company type | Public |
ISIN | INE361B01024 |
Industrie | Pharmaceuticals |
Gegründet | 12 October 1990 |
Hauptsitz | Divi Towers, Cyber Hills, Gachibowli, , Indien |
Key people | |
Produkte | Active Pharmaceutical Ingredients Nutraceuticals |
Services | Custom synthesis |
Revenue | ![]() |
![]() | |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Owner |
|
Number of employees | 13,884 (2020) |
Subsidiaries |
|
Website | divislabs |
Footnotes / references [1][2][3][4] |
History
editThe company initially started developing commercial processes for the manufacturing of APIs and intermediates. Divi's Research Centre changed its name to Divi's Laboratories Limited in 1994 to signal its intent to enter the API and intermediates manufacturing industry.[12] Following this, the company established its first Manufacturing facility in 1995 at Choutuppal, Telangana.[1] In 2002, the company's second manufacturing facility commenced operations at Chippada near Visakhapatnam.[1]
The company went public with its initial public offering (IPO) on 17 February 2003.[13][12] In 2010, the company established a research centre in Hyderabad.[1]
Products and services
editActive pharmaceutical ingredients (APIs) and intermediates
editDivi's Laboratories has between 60 and 85% global market share in generic naproxen, dextromethorphan and gabapentin APIs.[14] The company currently has between 20 and 30% global market share in pregabalin and methylamine APIs.[14] The company's API production is backwards integrated.[15]
Custom synthesis
editDivi's Laboratories custom synthesis division provides contract development and manufacturing (CDMO) services and contract research and manufacturing services (CRAMS).[15] The company's clients include 6 of the top 10 largest multinational pharmaceutical companies.[16]
Nutraceuticals
editDivi's Nutraceuticals is a subsidiary of Divi's Laboratories, and manufacturers and supplies over 80 forms of carotenoids and vitamins.[10] Divi's Nutraceuticals was founded in 2006 as a subsidiary of Divi's Laboratories.[10]
Facilities
editThe company has three manufacturing facilities and three R&D centres across India:[1]
Fertigungsindustrie
edit- Choutuppal Unit - Lingojigudem village, Choutuppal mandal, Yadadri Bhuvanagiri district, Telangana
- DC SEZ Unit - Lingojigudem village, Choutuppal mandal, Yadadri Bhuvanagiri district, Telangana
- Export Oriented Unit - Chippada village, Bheemunipatnam mandal, Visakhapatnam district, Andhra Pradesh
- Divi's Pharma SEZ Unit - Chippada village, Bheemunipatnam mandal, Visakhapatnam district, Andhra Pradesh
- DSN SEZ Unit - Chippada village, Bheemunipatnam mandal, Visakhapatnam district, Andhra Pradesh
- DCV SEZ Unit - Chippada village, Bheemunipatnam mandal, Visakhapatnam district, Andhra Pradesh
References
edit- ^ a b c d e f g h i j Laboratories, Divi's. "Annual Report" (PDF). divislabs.com. Archived (PDF) from the original on 18 October 2020.
- ^ a b "Divi's Laboratories Ltd Company profile". Bloomberg L.P. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
- ^ "Latest Shareholding Pattern - Divi's Laboratories Ltd". trendlyne.com. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
- ^ Laboratories, Divi's. "Subsidiary Financials" (PDF). divislabs.com. Archived (PDF) from the original on 18 October 2020.
- ^ "Company Profile-DIVIS LAB". Dynamic Levels. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
- ^ "Company Profile for Divi's Laboratories Ltd". Reuters. Archived from the original on 18 October 2017. Retrieved 15 September 2020.
- ^ "DIVI'S LABORATORIES LIMITED - Company, directors and contact details | Zauba Corp". www.zaubacorp.com. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
- ^ "Top API Manufacturing Company In Hyderabad, India & World | DivisLabs". Divis Laboratories World’s largest API manufacturing facility. Archived from the original on 12 August 2020. Retrieved 15 September 2020.
- ^ Bradstreet, Dun. "Divi's Laboratories company profile". dnb.com. Archived from the original on 18 October 2020.
- ^ a b c Divis Nutraceuticals (14 September 2021). "Press Release: Divi's Nutraceuticals launches CaroNat for natural food and beverage coloration". Divi's Nutraceuticals. Retrieved 27 July 2022.
- ^ "Top Pharmaceuticals & Drugs Stocks in India by Market Capitalisation". www.moneycontrol.com. Archived from the original on 13 January 2023. Retrieved 15 February 2023.
- ^ a b "Divis Laboratories > Company History > Pharmaceuticals > Company History of Divis Laboratories - BSE: 532488, NSE: DIVISLAB". moneycontrol.com. Archived from the original on 6 June 2020. Retrieved 17 September 2020.
- ^ "Divis Labs Fixes Rs 130 Per Share As Floor Price For IPO". The Financial Express. 11 February 2003. Archived from the original on 17 March 2018. Retrieved 18 September 2020.
- ^ a b Khandekar, Siddhant; Shah, Mitesh; Agarwal, Sudarshan (30 May 2021). "Divi's Laboratories (DIVLAB)" (PDF). ICICI Direct. p. 1. Archived (PDF) from the original on 12 October 2022. Retrieved 16 May 2022.
- ^ a b Sonavane, Ravindra N. (10 August 2020). "Divi's Labs beats drugmakers to become India's 2nd most valuable pharma company". mint. Archived from the original on 15 August 2020. Retrieved 16 May 2022.
- ^ Jauhari, Ujjval (8 February 2021). "Divi's Labs' Dec quarter show is strong but stock remains pricey". mint. Archived from the original on 6 April 2023. Retrieved 16 May 2022.